Sun Pharmaceutical Industries has announced that it will acquire Organon & Co., a deal that will cost around $11.75 billion in total cash, which includes the amount to pay off Organon’s debt obligation.
Under this agreement, Sun Pharma will be paying $14 per share in order to acquire all of Organon’s stock. This amount is nearly 24% above the most recent price that was recorded by Organon. In addition, Organon has total debts worth $8.6 billion as of December 2025. Initially, Organon was a subsidiary of Merck & Co before being separated from its parent firm to operate independently in 2021. Of late, they have been experiencing financial difficulties, as shown by a decrease in revenues by 5% in the final quarter and a loss of $205 million.
Sun Pharma’s Executive Chairman, Dilip Shanghvi, said that Organon’s products, capabilities, and global presence match well with Sun Pharma’s business. He believes that the acquisition of the two companies will create a stronger, more diverse business platform. valued at over $40 billion, plans to fund this deal with its existing cash and bank loans. The company has been trying to expand its business into other healthcare areas such as dermatology, cancer treatment, and obesity care.
You might like this also: Gautam Adani Overtakes Mukesh Ambani as Asia’s Richest
Sun Pharma has been under similar pressures in the United States, which is the primary market for the company, due to policy changes that have impacted its profits. As a way of mitigating its risks, the company is exploring the idea of establishing its production facilities in the United States. Generally, this acquisition is set to increase Sun Pharma’s standing in the international business environment.
